Data from a multinational phase III trial were analyzed to evaluate the use of in- and outpatient services for 373 patients with metastatic colorectal cancer being administered uracil/tegafur (in a molar ratio of 4:1 [UFT]) plus
Dan Ollendorf, MPH
Advertisement
Articles by Dan Ollendorf, MPH
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Delays Decision on Subcutaneous Isatuximab in Multiple Myeloma
2
Autogene Cevumeran & The Future of Personalized Cancer Vaccines
3
New Frontiers in Adjuvant Care: Evaluating Elacestrant in the ELEGANT Trial
4
CD39/PD-L1 Inhibition May Improve pCR Rate in Resectable NSCLC
5